Visionary Education Technology (US:GV) Prnewswire·2025-10-22 13:30Core Viewpoint - Visionary Holdings Inc. has signed a strategic cooperation agreement with Jiangsu Yike Regenerative Medical Technology Co., Ltd. to establish a joint venture, Visionary Yike Stemcell Technologies Inc., aimed at advancing stem cell research and commercialization globally [1][5]. Group 1: Joint Venture Details - The joint venture will focus on stem cell therapy, immune cell engineering, and AI-supported anti-aging diagnostics, leveraging Yike's proprietary platform and GV's global market infrastructure [3]. - GV will hold an 85% equity stake in the joint venture, while Yike will hold 15% [3]. - The joint venture aims to create a vertically integrated regenerative medicine enterprise encompassing R&D, trials, manufacturing, and global sales [3]. Group 2: Location and Infrastructure - The headquarters for the joint venture is proposed to be located at GV's property in Toronto, which spans over 40,000 square meters [2]. - The parties are evaluating the feasibility of developing cleanrooms, low-temperature biostorage, and related infrastructures to support future operations [2]. Group 3: Strategic Importance - The establishment of the joint venture is seen as a transformative milestone for GV's global health strategy, with potential for long-term value creation [4]. - This collaboration is expected to enhance GV's positioning in the North American stem cell sector and reflects a commitment to global innovation and shareholder value [5]. Group 4: Company Background - Visionary Holdings Inc. is a technology-driven multinational enterprise focused on innovative education, AI applications, and high-tech healthcare solutions, operating across North America and Asia [6]. - Jiangsu Yike Regenerative Medicine specializes in regenerative medicine and precision anti-aging technologies, holding numerous international patents and certifications [7].